Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma

doi:10.1007/s10620-017-4615-x

Review

. 2017 Aug;62(8):1872-1880.

doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19.

Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma

Affiliations

¹ Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy. serena.dematteis@irst.emr.it.
² Immunotherapy and Cell Therapy Unit, IRST IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
³ Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
⁴ Department of Medical Oncology, IRST IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
⁵ Campus Bio-Medico, University of Rome, Via Àlvaro del Portillo, 21, 00128, Rome, Italy.
⁶ Department of Internal Medicine, Ospedale per gli Infermi, Viale Stradone, 9, 48018, Faenza, Italy.
⁷ Department of General Surgery, Morgagni-Pierantoni Hospital, Via Carlo Forlanini, 34, 47121, Forlì, Italy.
⁸ Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
⁹ Internal Medicine and Hepatology Unit, University Campus Bio-Medico, Via Àlvaro del Portillo, 21, 00128, Rome, Italy.
¹⁰ Medical Oncology, University Hospital, University of Cagliari, SS 554 km 4.500, Monserrato, Cagliari, Italy.

PMID: 28527050
DOI: 10.1007/s10620-017-4615-x

Free article

Review

Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma

Serena De Matteis et al. Dig Dis Sci. 2017 Aug.

Free article

. 2017 Aug;62(8):1872-1880.

doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19.

Authors

Affiliations

¹ Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy. serena.dematteis@irst.emr.it.
² Immunotherapy and Cell Therapy Unit, IRST IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
³ Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
⁴ Department of Medical Oncology, IRST IRCCS, Via Maroncelli, 40, 47014, Meldola, Italy.
⁵ Campus Bio-Medico, University of Rome, Via Àlvaro del Portillo, 21, 00128, Rome, Italy.
⁶ Department of Internal Medicine, Ospedale per gli Infermi, Viale Stradone, 9, 48018, Faenza, Italy.
⁷ Department of General Surgery, Morgagni-Pierantoni Hospital, Via Carlo Forlanini, 34, 47121, Forlì, Italy.
⁸ Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
⁹ Internal Medicine and Hepatology Unit, University Campus Bio-Medico, Via Àlvaro del Portillo, 21, 00128, Rome, Italy.
¹⁰ Medical Oncology, University Hospital, University of Cagliari, SS 554 km 4.500, Monserrato, Cagliari, Italy.

PMID: 28527050
DOI: 10.1007/s10620-017-4615-x

Abstract

Sirtuins (SIRT), first described as nicotinamide adenine dinucleotide (NAD⁺)-dependent type III histone deacetylases, are produced by cells to support in the defense against chronic stress conditions such as metabolic syndromes, neurodegeneration, and cancer. SIRT-3 is one of the most studied members of the mitochondrial sirtuins family. In particular, its involvement in metabolic diseases and its dual role in cancer have been described. In the present review, based on the evidence of SIRT-3 involvement in metabolic dysfunctions, we aimed to provide an insight into the multifaceted role of SIRT-3 in many solid and hematological tumors with a particular focus on hepatocellular carcinoma (HCC). SIRT-3 regulatory effect and involvement in metabolism dysfunctions may have strong implications in HCC development and treatment. Research literature widely reports the relationship between metabolic disorders and HCC development. This evidence suggests a putative bridge role of SIRT-3 between metabolic diseases and HCC. However, further studies are necessary to demonstrate such interconnection.

Keywords: Hepatocellular carcinoma; Metabolism; SIRT-3; Tumor suppressor.

PubMed Disclaimer

Cited by

Sorafenib and metformin: to be, or not to be, that is the question.
Orsi G, Casadei-Gardini A. Orsi G, et al. Hepatobiliary Surg Nutr. 2019 Aug;8(4):411-413. doi: 10.21037/hbsn.2019.04.01. Hepatobiliary Surg Nutr. 2019. PMID: 31489317 Free PMC article. No abstract available.
CD90 affects the biological behavior and energy metabolism level of gastric cancer cells by targeting the PI3K/AKT/HIF-1α signaling pathway.
Gao L, Li J, He J, Liang L, He Z, Yue C, Jin X, Luo G, Zhou Y. Gao L, et al. Oncol Lett. 2021 Mar;21(3):191. doi: 10.3892/ol.2021.12451. Epub 2021 Jan 7. Oncol Lett. 2021. PMID: 33574930 Free PMC article.
Biochemical Mechanisms of Sirtuin-Directed Protein Acylation in Hepatic Pathologies of Mitochondrial Dysfunction.
McGinnis CD, Jennings EQ, Harris PS, Galligan JJ, Fritz KS. McGinnis CD, et al. Cells. 2022 Jun 28;11(13):2045. doi: 10.3390/cells11132045. Cells. 2022. PMID: 35805129 Free PMC article. Review.
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A. De Matteis S, et al. Int J Mol Sci. 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503. Int J Mol Sci. 2019. PMID: 30917505 Free PMC article.
Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma.
Pant K, Peixoto E, Richard S, Gradilone SA. Pant K, et al. Cells. 2020 Mar 23;9(3):780. doi: 10.3390/cells9030780. Cells. 2020. PMID: 32210140 Free PMC article. Review.

See all "Cited by" articles

References

1. Cell Cycle. 2007 Nov 1;6(21):2669-77 - PubMed
1. Biochem Biophys Res Commun. 2014 Jan 3;443(1):156-60 - PubMed
1. Oncol Rep. 2013 Sep;30(3):1323-8 - PubMed
1. J Lifestyle Med. 2014 Sep;4(2):80-5 - PubMed
1. Int J Oncol. 2013 Nov;43(5):1420-30 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Institutional Repository of University of Modena and Reggio Emilia (IRIS UNIMORE)
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Cell Cycle. 2007 Nov 1;6(21):2669-77 - PubMed

[2] Cell Cycle. 2007 Nov 1;6(21):2669-77 - PubMed

[3] Biochem Biophys Res Commun. 2014 Jan 3;443(1):156-60 - PubMed

[4] Biochem Biophys Res Commun. 2014 Jan 3;443(1):156-60 - PubMed

[5] Oncol Rep. 2013 Sep;30(3):1323-8 - PubMed

[6] Oncol Rep. 2013 Sep;30(3):1323-8 - PubMed

[7] J Lifestyle Med. 2014 Sep;4(2):80-5 - PubMed

[8] J Lifestyle Med. 2014 Sep;4(2):80-5 - PubMed

[9] Int J Oncol. 2013 Nov;43(5):1420-30 - PubMed

[10] Int J Oncol. 2013 Nov;43(5):1420-30 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma

Affiliations

Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical